Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -99.62% is 153% below its 5-year average of 188.84%, near the low end of its 5-year range (-149.19%–1421.66%).
149.11% below its 12-month average of -39.99%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -31.56%.
RETURN ON ASSETS (ROA)
-99.62%
RETURN ON ASSETS (ROA) AVG TTM
-39.99%
RETURN ON ASSETS (ROA) AVG 3Y
-67.06%
RETURN ON ASSETS (ROA) AVG 5Y
188.84%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-149.11%
CURRENT VS 3Y AVG
-48.55%
CURRENT VS 5Y AVG
-152.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.96%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
-299.12%
vs the sector median at left
Context Therapeutics Inc.
Market Cap
$30.92M
Return on Assets (ROA)
-99.62%
TTM Avg
-39.99%
3Y Avg
-67.06%
5Y Avg
188.84%
Market Cap
$30.65M
Return on Assets (ROA)
-116.76%
TTM Avg
-76.53%
3Y Avg
-78.60%
5Y Avg
-71.54%
Market Cap
$31.36M
Return on Assets (ROA)
-39.14%
TTM Avg
-11.59%
3Y Avg
6.23%
5Y Avg
18.56%
Market Cap
$32.31M
Return on Assets (ROA)
-277.36%
TTM Avg
-524.61%
3Y Avg
-478.10%
5Y Avg
-316.43%
Market Cap
$32.32M
Return on Assets (ROA)
-45.77%
TTM Avg
-31.61%
3Y Avg
-54.99%
5Y Avg
-58.45%
Market Cap
$28.43M
Return on Assets (ROA)
-87.08%
TTM Avg
-72.41%
3Y Avg
-58.48%
5Y Avg
-50.84%
Market Cap
$33.42M
Return on Assets (ROA)
-114.53%
TTM Avg
-107.26%
3Y Avg
-84.46%
5Y Avg
-72.21%
Market Cap
$33.52M
Return on Assets (ROA)
-42.84%
TTM Avg
-15.31%
3Y Avg
-31.73%
5Y Avg
-29.34%
Market Cap
$27.31M
Return on Assets (ROA)
-49.53%
TTM Avg
-17.16%
3Y Avg
-133.18%
5Y Avg
-213.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | $30.92M | -99.62% | -39.99% | -67.06% | 188.84% |
| CervoMed Inc. (CRVO)vs › | $30.65M | -116.76% | -76.53% | -78.60% | -71.54% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | -39.14% | -11.59% | 6.23% | 18.56% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | -277.36% | -524.61% | -478.10% | -316.43% |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | -45.77% | -31.61% | -54.99% | -58.45% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | -87.08% | -72.41% | -58.48% | -50.84% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.42M | -114.53% | -107.26% | -84.46% | -72.21% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | -42.84% | -15.31% | -31.73% | -29.34% |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | -49.53% | -17.16% | -133.18% | -213.67% |
| Accuray Incorporated (ARAY)vs › | $35.89M | -11.09% | -5.71% | -4.17% | -3.19% |
ROA
-99.6%
ROE
-120.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -52.74% |
| 2024-12-31 | -27.24% |
| 2023-12-31 | -149.19% |
| 2022-12-31 | -39.08% |
| 2021-12-31 | -20.38% |
| 2020-12-31 | 1421.66% |
| 2019-12-31 | -2333.78% |
